All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-02-01T13:24:37.000Z

What new technologies are available in the field of CAR T manufacturing?

By Alia Mohamed
Featured
Bruce Levine
Feb 1, 2020
Share:

Bookmark this article

The AML Global Portal are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Bruce Levine from the University of Pennsylvania, Philadelphia, US, discusses what new technologies are available in the field of CAR T manufacturing?

Bruce Levine talks about novel technologies in CAR T cell manufacturing that will increase the effectiveness of CAR T such as the incorporation of biomarkers as a prognostic factor for response. In addition to this, he explains strategies such as shorting the process of CAR T manufacturing to reduce overall costs.

What new technologies are available in the field of CAR T manufacturing?

More about...
CAR therapyCAR-T 2020

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Related articles

Add bookmark

CAR-T 2020 | Cytopenia in CART — the prolonged threat of infection

Cytopenia has been reported following lymphodepletion and CAR T-cell infusion with axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tis-cel).

Mar 2, 2020
Add bookmark

CAR-T 2020 | Cytopenia in CART — the prolonged threat of infection

Cytopenia has been reported following lymphodepletion and CAR T-cell infusion with axicabtagene ciloleucel (axi-cel) and...

Mar 2, 2020
Add bookmark

How could nanobody-based tri-specific CAR T cells improve the treatment of AML?

During the 2nd European CAR T Cell Meeting in Sitges, ES, the AML Global Portal was delighted to speak to Warren Hazelton, University College London, London, UK. We...

Jan 30, 2020
Add bookmark

How could nanobody-based tri-specific CAR T cells improve the treatment of AML?

During the 2nd European CAR T Cell Meeting in Sitges, ES, the AML Global Portal was delighted to speak to Warren...

Jan 30, 2020

Newsletter

Subscribe to get the best content related to AML delivered to your inbox